BIOTECH EXPERIENCE & AFFILIATIONS

BIOTECH EXPERIENCE & AFFILIATIONS

Advanced numerous public health interventions to reduce disease burden and protect against chronic and infectious diseases and environmental threats, as well as several first-in-class genetically engineered commercial products.
Advanced numerous public health interventions to reduce disease burden and protect against chronic and infectious diseases and environmental threats, as well as several first-in-class genetically engineered commercial products.
HIGHLIGHTS SUMMARY
HIGHLIGHTS SUMMARY
  • Part of technical team that transitioned testing of US blood supply from immunoassay to more sensitive molecular tests for the safety of nation's blood supply and launched APTIMA infectious disease molecular diagnostic platforms (NASDAQ:GPRO)
  • Performed global health fieldwork and international development in Sub-Saharan Africa with interventions targeting HIV, tuberculosis, malaria, malnutrition, sanitation, clean water, healthy air, agriculture, and health education to reduce burden of chronic and infectious diseases
  • Served as strategist and technology analyst across sectors for publicly-traded biotechnology company (NASDAQ:XON) and FORBES 400 largest individual American biotech investor
  • Part of technical team that transitioned testing of US blood supply from immunoassay to more sensitive molecular tests for the safety of nation's blood supply and launched APTIMA infectious disease molecular diagnostic platforms (NASDAQ:GPRO)
  • Performed global health fieldwork and international development in Sub-Saharan Africa with interventions targeting HIV, tuberculosis, malaria, malnutrition, sanitation, clean water, healthy air, agriculture, and health education to reduce burden of chronic and infectious diseases
  • Served as strategist and technology analyst across sectors for publicly-traded biotechnology company (NASDAQ:XON) and FORBES 400 largest individual American biotech investor
  • Part of technical team that transitioned testing of US blood supply from immunoassay to more sensitive molecular tests for the safety of nation's blood supply and launched APTIMA infectious disease molecular diagnostic platforms (NASDAQ:GPRO)
  • Performed global health fieldwork and international development in Sub-Saharan Africa with interventions targeting HIV, tuberculosis, malaria, malnutrition, sanitation, clean water, healthy air, agriculture, and health education to reduce burden of chronic and infectious diseases
  • Served as strategist and technology analyst across sectors for publicly-traded biotechnology company (NASDAQ:XON) and FORBES 400 largest individual American biotech investor

EXPERIENCE
EXPERIENCE
TECHNOLOGY & BUSINESS STRATEGY
TECHNOLOGY & BUSINESS STRATEGY
  • Led strategic business and technology innovation functions at large publicly traded multi-national biotechnology company (NASDAQ:XON)
  • Diligenced over $400M in biotechnology acquisitions (see list)
  • Served as technology and business analyst for FORBES 400 largest individual American biotech investor
  • Led strategic business and technology innovation functions at large publicly traded multi-national biotechnology company (NASDAQ:XON)
  • Diligenced over $400M in biotechnology acquisitions (see list)
  • Served as technology and business analyst for FORBES 400 largest individual American biotech investor
  • Led strategic business and technology innovation functions at large publicly traded multi-national biotechnology company (NASDAQ:XON)
  • Diligenced over $400M in biotechnology acquisitions (see list)
  • Served as technology and business analyst for FORBES 400 largest individual American biotech investor
CORPORATE STRATEGY | M&A DILIGENCE - click to read more
Advised C-suite executives on corporate technology strategy. Led internal, external, and open innovation functions to advance new product development, licensing, commercial partnerships, joint ventures, and strategic alliances for large publicly traded multi-national biotechnology company.

Learn more about corporate technology innovation strategy and M&A diligence experience supporting over $400M in biotechnology acquisitions:
Advised C-suite executives on corporate technology strategy. Led internal, external, and open innovation functions to advance new product development, licensing, commercial partnerships, joint ventures, and strategic alliances for large publicly traded multi-national biotechnology company.

Learn more about corporate technology innovation strategy and M&A diligence experience supporting over $400M in biotechnology acquisitions:
BIOTECHNOLOGY DEVELOPMENT & COMMERCIALIZATION
BIOTECHNOLOGY DEVELOPMENT & COMMERCIALIZATION
  • Marketed and advanced several FDA, USDA, and EPA regulated first-in-class gene-edited and genetically modified organisms for food, environmental, and public health applications (fish, fruit, insects, microbes) (NASDAQ:XON)
  • Developed current FDA approved molecular tests ensuring safety of US blood supply (HIV, HCV, HBV, West Nile Virus) (NASDAQ:GPRO)
  • Launched first FDA cleared combined Chlamydia and Gonorrhea molecular tests and Aptima molecular diagnostic platform
  • Marketed and advanced several FDA, USDA, and EPA regulated first-in-class gene-edited and genetically modified organisms for food, environmental, and public health applications (fish, fruit, insects, microbes) (NASDAQ:XON)
  • Developed current FDA approved molecular tests ensuring safety of US blood supply (HIV, HCV, HBV, West Nile Virus) (NASDAQ:GPRO)
  • Launched first FDA cleared combined Chlamydia and Gonorrhea molecular tests and Aptima molecular diagnostic platform (NASDAQ:GPRO)
  • Marketed and advanced several FDA, USDA, and EPA regulated first-in-class gene-edited and genetically modified organisms for food, environmental, and public health applications (fish, fruit, insects, microbes) (NASDAQ:XON)
  • Developed current FDA approved molecular tests ensuring safety of US blood supply (HIV, HCV, HBV, West Nile Virus) (NASDAQ:GPRO)
  • Launched first FDA cleared combined Chlamydia and Gonorrhea molecular tests and Aptima molecular diagnostic platform (NASDAQ:GPRO)
BIOTECHNOLOGY DEVELOPMENT & COMMERCIALIZATION - click to read more
Learn more about new product development experience:

Seeking investment for advancing new biotech ventures and technology development initiatives:
Learn more about new product development experience:

Seeking investment for advancing new biotech ventures and technology development initiatives:
PUBLIC HEALTH INNOVATION
PUBLIC HEALTH INNOVATION
  • Participated in transitioning of testing of US blood supply from immunoassay to more sensitive molecular testing (NASDAQ:GPRO)
  • Facilitated protocol design and deployment of pioneering HIV/CD4 mobile testing in Sub-Saharan Africa to ensure efficacy of HIV anti-retroviral therapies (ART) in rural low resource settings
  • Performed global health fieldwork and international development in Sub-Saharan Africa with interventions targeting HIV, tuberculosis, malaria, malnutrition, sanitation, clean water, healthy air, agriculture, and health education to reduce burden of chronic and infectious diseases
  • Participated in transitioning of testing of US blood supply from immunoassay to more sensitive molecular testing (NASDAQ:GPRO)
  • Facilitated protocol design and deployment of pioneering HIV/CD4 mobile testing in Sub-Saharan Africa to ensure efficacy of HIV anti-retroviral therapies (ART) in rural low resource settings
  • Performed global health fieldwork and international development in Sub-Saharan Africa with interventions targeting HIV, tuberculosis, malaria, malnutrition, sanitation, clean water, healthy air, agriculture, and health education to reduce burden of chronic and infectious diseases
  • Participated in transitioning of testing of US blood supply from immunoassay to more sensitive molecular testing (NASDAQ:GPRO)
  • Facilitated protocol design and deployment of pioneering HIV/CD4 mobile testing in Sub-Saharan Africa to ensure efficacy of HIV anti-retroviral therapies (ART) in rural low resource settings
  • Performed global health fieldwork and international development in Sub-Saharan Africa with interventions targeting HIV, tuberculosis, malaria, malnutrition, sanitation, clean water, healthy air, agriculture, and health education to reduce burden of chronic and infectious diseases
PUBLIC HEALTH INNOVATION - click to read more
  • Helped flatten the curve on epidemic STIs and infectious diseases with development of APTIMA molecular diagnostic platform (NASDAQ:GPRO)
  • Developed biodefense and threat detection systems for bioterrorism agents and infectious diseases (NASDAQ:NGEN)
  • Led corporate environmental biotechnology strategy, public health, and One Health initiatives under a former Commanding General of the US Army Corps of Engineers (NASDAQ:XON)
  • Responded to epidemics including: COVID-19 pandemic, Zika, dengue, malaria, tuberculosis, HIV, influenza, Chlamydia, and Gonorrhea
  • Engaged federal, state, and local government agencies and briefed US Congress to advance high-profile new technologies for the public health
  • Advanced novel biotechnologies including:
  • Genetically engineered mosquitoes for vector control to reduce spread of Zika, dengue, yellow fever, chikungunya, and malaria
  • Viral-based vaccines for disease prevention and biodefense countermeasures
  • Environmental health interventions for bioremediation of emerging contaminants of concern (COCs)
  • Chronic disease diagnostic technologies for Alzheimer’s disease and cancer profiling
  • Genetically engineered salmon for more sustainable food production via aquaculture with reduced environmental impacts
  • Animal cloning of elite genetics to improve food systems and accessibility to quality protein
  • Helped flatten the curve on epidemic STIs and infectious diseases with development of APTIMA molecular diagnostic platform (NASDAQ:GPRO)
  • Developed biodefense and threat detection systems for bioterrorism agents and infectious diseases (NASDAQ:NGEN)
  • Led corporate environmental biotechnology strategy, public health, and One Health initiatives under a former Commanding General of the US Army Corps of Engineers (NASDAQ:XON)
  • Responded to epidemics including: COVID-19 pandemic, Zika, dengue, malaria, tuberculosis, HIV, influenza, Chlamydia, and Gonorrhea
  • Engaged federal, state, and local government agencies and briefed US Congress to advance high-profile new technologies for the public health
  • Advanced novel biotechnologies including:
  • Genetically engineered mosquitoes for vector control to reduce spread of Zika, dengue, yellow fever, chikungunya, and malaria
  • Viral-based vaccines for disease prevention and biodefense countermeasures
  • Environmental health interventions for bioremediation of emerging contaminants of concern (COCs)
  • Chronic disease diagnostic technologies for Alzheimer’s disease and cancer profiling
  • Genetically engineered salmon for more sustainable food production via aquaculture with reduced environmental impacts
  • Animal cloning of elite genetics to improve food systems and accessibility to quality protein
  • Helped flatten the curve on epidemic STIs and infectious diseases with development of APTIMA molecular diagnostic platform (NASDAQ:GPRO)
  • Developed biodefense and threat detection systems for bioterrorism agents and infectious diseases (NASDAQ:NGEN)
  • Led corporate environmental biotechnology strategy, public health, and One Health initiatives under a former Commanding General of the US Army Corps of Engineers (NASDAQ:XON)
  • Responded to epidemics including: COVID-19 pandemic, Zika, dengue, malaria, tuberculosis, HIV, influenza, Chlamydia, and Gonorrhea
  • Engaged federal, state, and local government agencies and briefed US Congress to advance high-profile new technologies for the public health
  • Advanced novel biotechnologies including:
  • Genetically engineered mosquitoes for vector control to reduce spread of Zika, dengue, yellow fever, chikungunya, and malaria
  • Viral-based vaccines for disease prevention and biodefense countermeasures
  • Environmental health interventions for bioremediation of emerging contaminants of concern (COCs)
  • Chronic disease diagnostic technologies for Alzheimer’s disease and cancer profiling
  • Genetically engineered salmon for more sustainable food production via aquaculture with reduced environmental impacts
  • Animal cloning of elite genetics to improve food systems and accessibility to quality protein

FORMER AFFILIATIONS
FORMER AFFILIATIONS
COMPANIES
  • Gen-Probe
  • Nanogen
  • Vectrant Technologies
  • Exonhit Therapeutics
  • Intrexon
ACADEMIC RESEARCH INSTITUTIONS
  • University of California San Diego | Department of Biology
  • The Scripps Research Institute | Department of Immunology
  • Scripps Institution of Oceanography | Marine Biology Research Division
  • George Mason University | Department of Global and Community Health
VOLUNTEER ORGANIZATIONS
  • St. Gabriel's Hospital - Malawi
  • American Lung Association
COMPANIES
  • Gen-Probe
  • Nanogen
  • Vectrant Technologies
  • Exonhit Therapeutics
  • Intrexon
ACADEMIC RESEARCH INSTITUTIONS
  • University of California San Diego | Department of Biology
  • The Scripps Research Institute | Department of Immunology
  • Scripps Institution of Oceanography | Marine Biology Research Division
  • George Mason University | Department of Global and Community Health
VOLUNTEER ORGANIZATIONS
  • St. Gabriel's Hospital - Malawi
  • American Lung Association

BIOTECHNOLOGY DEVELOPMENT & INNOVATION
BIOTECHNOLOGY DEVELOPMENT & INNOVATION
EXPERTISE & BIOTECH EXPERIENCE
  • Corporate Strategy
  • Business and Technology Analysis
  • Corporate, Strategic, and Technical Communications
  • Marketing and Branding
  • Business Development and Strategic Alliances
  • Corporate Development and M&A Diligence
  • New Product Development and Commercialization
  • Basic and Applied Research
  • Public Health and Global Health Interventions and Messaging
  • Government Relations
  • Not-for-Profit and Philanthropic Engagements
MARKET SECTOR EXPERIENCE:
HEALTH, FOOD & ENVIRONMENT
  • Medical diagnostics
  • Therapeutics
  • Vaccines
  • Sustainable food and protein production via genetic and genome engineering technologies
  • Environmental health technologies for:
  • Biosecurity, biothreat detection, and biodefense countermeasures (diagnostics, therapeutics, vaccines)
  • Infectious disease vector control
  • Bioremediation and environmental cleanup of contaminants of concern (COCs)
  • Carbon capture and up-cycling
EXPERTISE & BIOTECH EXPERIENCE
  • Corporate Strategy
  • Business and Technology Analysis
  • Corporate, Strategic, and Technical Communications
  • Marketing and Branding
  • Business Development and Strategic Alliances
  • Corporate Development and M&A Diligence
  • New Product Development and Commercialization
  • Basic and Applied Research
  • Public Health and Global Health Interventions and Messaging
  • Government Relations
  • Not-for-Profit and Philanthropic Engagements
MARKET SECTOR EXPERIENCE: HEALTH, FOOD & ENVIRONMENT
  • Medical diagnostics
  • Therapeutics
  • Vaccines
  • Sustainable food and protein production via genetic and genome engineering technologies
  • Environmental health technologies for:
  • Biosecurity, biothreat detection, and biodefense countermeasures (diagnostics, therapeutics, vaccines)
  • Infectious disease vector control
  • Bioremediation and environmental cleanup of contaminants of concern (COCs)
  • Carbon capture and up-cycling
Specialized fields and disciplines
  • Biotechnology Development
  • Biopharma
  • Medical Device and Healthcare Technologies
  • Synthetic Biology and Genetic Engineering
  • Public Health
  • Global Health
  • Epidemiology
  • Biodefense and Biosecurity
  • Environmental Health
  • One Health
Specialized fields and disciplines
  • Biotechnology Development
  • Biopharma
  • Medical Device and Healthcare Technologies
  • Synthetic Biology and Genetic Engineering
  • Public Health
  • Global Health
  • Epidemiology
  • Biodefense and Biosecurity
  • Environmental Health
  • One Health
PRODUCT DEVELOPMENT & CORPORATE STRATEGY
PRODUCT DEVELOPMENT & CORPORATE STRATEGY
Learn more about new product development experience:

Learn more about corporate technology innovation strategy and M&A diligence experience supporting over $400M in biotechnology acquisitions:

Currently investing to advance new biotech ventures and technology development initiatives:
Learn more about new product development experience:

Learn more about corporate technology innovation strategy and M&A diligence experience supporting over $400M in biotechnology acquisitions:

Currently investing to advance new biotech ventures and technology development initiatives: